Physician profile
Dylan Bobrow
NPI 1164006136
$745.34
in general payments reported to CMS, 2019-2025
9 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $39.58 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.48 | 2025 | Jascayd |
| Astrazeneca Pharmaceuticals Lp | $141.86 | 2024-2025 | Tezspire |
| Intuitive Surgical, INC. | $125.75 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $113.36 | 2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $82.86 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $29.70 | 2025 | |
| Mallinckrodt Hospital Products INC. | $24.79 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $22.72 | 2024 | Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $20.82 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Bobrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.